DoubleVerify Holdings, Inc. DV 深 沪
已收盘 05-22 16:00:00 美东时间
9.83
+0.310
+3.26%
华盛通- 最 高9.84
- 今 开9.64
- 成交量 235.09万股
- 最 低 9.55
- 昨 收 9.52
- 总市值 15.09亿
- 52周最高 16.82
- 市盈率 静 32.35
- 换手率 1.53%
- 52周最低 7.64
- 委 比 88.56%
- 总股本 1.53亿
- 历史最高 48.42
- 量 比 0.54
- 振 幅 3.05%
- 历史最低 7.64
- 每 手 1
- 风险率 2.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多DoubleVerify Delivers Global Media Quality Measurement for LinkedIn Audience Network, Elevating Transparency for B2B Advertisers
DoubleVerify (DV) has launched global post-bid measurement capabilities on the LinkedIn Audience Network (LAN), enabling advertisers to measure key media quality signals such as invalid traffic, viewability, brand suitability, and intended geography. This independent verification empowers advertisers to make informed investment decisions and improve campaign effectiveness. DV’s solution also offers pre-bid controls for proactive inventory analysi...
05-21 13:00
DoubleVerify Launches AI-Powered Content-Level Controls on Meta Threads, Strengthening Brand Protection
DoubleVerify (DV) introduces AI-powered pre-screen content controls on Meta Threads, enabling advertisers to avoid unsuitable content before ads are served. This enhances brand protection and improves campaign performance. DV’s pre-screen controls evaluate content before impressions are transacted, helping advertisers avoid placements that fall below their defined brand suitability thresholds. Post-bid measurement then analyzes delivered impressi...
05-18 13:00
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
DoubleVerify expands Philippines team in APAC investment push
DoubleVerify expands Philippines team in APAC investment push DoubleVerify expanded investment in Philippines with a larger local team, reinforcing broader push across Asia-Pacific. Expansion added two Manila-based hires, including Integrated Solutions Director Jeff Orpilla, to support brands, agenc
05-12 12:05
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Goldman Sachs Maintains Neutral on DoubleVerify Holdings, Raises Price Target to $12
Goldman Sachs analyst Eric Sheridan maintains DoubleVerify Holdings (NYSE:DV) with a Neutral and raises the price target from $10.5 to $12.
05-08 01:02
Global Study: Fueled by AI, CTV Fraud Schemes Surge 140% Globally
DoubleVerify's 2026 Global Insights report highlights that AI is driving a surge in sophisticated CTV fraud, with schemes increasing by 140% in Q1 2026 compared to Q1 2025. Fraudsters exploit inefficiencies in the ecosystem, targeting premium CTV spend. Key findings include persistent bot activity, a 10x rise in fraudulent apps, and significant financial losses for advertisers. Fraud patterns vary by region, with bots dominating North America and...
05-07 13:00
电话会总结 ｜ DoubleVerify(DV)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据DoubleVerify业绩会实录，以下是Q1 2026财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** Q1总营收达到1.81亿美元，同比增长10%。其中广告主营收占总营收90%，同比增长9%；社交测量营收同比增长23%；社交激活营收同比增长92%；测量营收同比增长16%；供应方营收占总营收10%，同比增长12%。 **盈利能力：** 调整后EBITDA为5500万美元，EBITDA利润率达到31%，较去年同期的27%显著提升。营收减去销售成本后的毛利率为82%。 **现金流状况：** Q1经营活动现金流净额为400万美元，受季末收
05-07 12:10
财报速睇 | DoubleVerify Holdings, Inc. 2026财年Q1营收1.81亿美元，同比增长9.6%；归母净利润0.06亿美元，同比增长171.5%
华盛资讯5月7日讯，DoubleVerify Holdings, Inc.公布2026财年Q1业绩，公司Q1营收1.81亿美元，同比增长9.6%，归母净利润0.06亿美元，同比增长171.5%。
05-07 08:06
CORRECTION: DoubleVerify Hldgs Q1 Adj. EPS $0.17 Beats $0.06 Estimate, Sales $180.800M Miss $181.415M Estimate
DoubleVerify Hldgs (NYSE:DV) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.06 by 183.33 percent. This is a 13.33 percent increase over earnings of $0.15 per share from the
05-07 07:27
